| Fady E Abou Rizk, MD | |
|
85 Spring Street, Pulmonary & Critical Care Medicine, Laconia, NH 03246-3113 | |
| (603) 527-2970 | |
| (603) 527-2874 |
| Full Name | Fady E Abou Rizk |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 22 Years |
| Location | 85 Spring Street, Laconia, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518124189 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 15098 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lakes Region General Hospital | Laconia, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Hospital-laconia | 7012326259 | 202 |
| Speare Memorial Hospital | 1153318068 | 39 |
News Archive
Grifols today announces that it has entered into a formal collaboration with the US Government alongside other health agencies, to treat COVID-19 disease.
Research suggests that levels of fibulin-3 in plasma and effusions may aid in determining the diagnosis and prognosis of pleural mesothelioma.
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
For years, bioengineer Yaling Liu has been in pursuit of the deadly tumor cell. Liu has been perfecting a microfluidic device the size of two quarters that has the ability to catch and release circulating tumor cells (CTCs)-cancer cells that circulate in a cancer patient's blood.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
› Verified 4 days ago
| Entity Name | Lrghealthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700976032 PECOS PAC ID: 8820908189 Enrollment ID: O20040303000982 |
News Archive
Grifols today announces that it has entered into a formal collaboration with the US Government alongside other health agencies, to treat COVID-19 disease.
Research suggests that levels of fibulin-3 in plasma and effusions may aid in determining the diagnosis and prognosis of pleural mesothelioma.
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
For years, bioengineer Yaling Liu has been in pursuit of the deadly tumor cell. Liu has been perfecting a microfluidic device the size of two quarters that has the ability to catch and release circulating tumor cells (CTCs)-cancer cells that circulate in a cancer patient's blood.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
› Verified 4 days ago
| Entity Name | Speare Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346402047 PECOS PAC ID: 1153318068 Enrollment ID: O20040823001172 |
News Archive
Grifols today announces that it has entered into a formal collaboration with the US Government alongside other health agencies, to treat COVID-19 disease.
Research suggests that levels of fibulin-3 in plasma and effusions may aid in determining the diagnosis and prognosis of pleural mesothelioma.
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
For years, bioengineer Yaling Liu has been in pursuit of the deadly tumor cell. Liu has been perfecting a microfluidic device the size of two quarters that has the ability to catch and release circulating tumor cells (CTCs)-cancer cells that circulate in a cancer patient's blood.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
› Verified 4 days ago
| Entity Name | Concord Hospital-laconia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053993741 PECOS PAC ID: 7012326259 Enrollment ID: O20210429001355 |
News Archive
Grifols today announces that it has entered into a formal collaboration with the US Government alongside other health agencies, to treat COVID-19 disease.
Research suggests that levels of fibulin-3 in plasma and effusions may aid in determining the diagnosis and prognosis of pleural mesothelioma.
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
For years, bioengineer Yaling Liu has been in pursuit of the deadly tumor cell. Liu has been perfecting a microfluidic device the size of two quarters that has the ability to catch and release circulating tumor cells (CTCs)-cancer cells that circulate in a cancer patient's blood.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fady E Abou Rizk, MD Po Box 1327, Laconia, NH 03247-1357 Ph: (603) 524-3211 | Fady E Abou Rizk, MD 85 Spring Street, Pulmonary & Critical Care Medicine, Laconia, NH 03246-3113 Ph: (603) 527-2970 |
News Archive
Grifols today announces that it has entered into a formal collaboration with the US Government alongside other health agencies, to treat COVID-19 disease.
Research suggests that levels of fibulin-3 in plasma and effusions may aid in determining the diagnosis and prognosis of pleural mesothelioma.
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
For years, bioengineer Yaling Liu has been in pursuit of the deadly tumor cell. Liu has been perfecting a microfluidic device the size of two quarters that has the ability to catch and release circulating tumor cells (CTCs)-cancer cells that circulate in a cancer patient's blood.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
› Verified 4 days ago
Nino Idoidze, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 | |
Farkhat Galiullin, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 Fax: 603-737-6713 | |
Dr. Mary-claire Sampas Paicopolis, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 85 Spring St, Laconia, NH 03246 Phone: 603-528-8555 Fax: 603-528-7668 | |
Noshi A Ishak, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 87 Spring Street, Laconia, NH 03246 Phone: 603-524-8896 Fax: 603-524-8796 | |
Gurpinder Singh, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 80 Highland Street, Laconia, NH 03246 Phone: 603-524-3211 Fax: 603-737-6713 | |
Shamai Kurbitaeva, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 347-844-2314 | |
Sharan Sharma, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 Fax: 603-737-6713 |